The PTAB May Be Taking a More Balanced Approach in Biotech and Pharmaceutical IPRs | Bloomberg BNA
Partner Michael Fuller wrote an article for the Bloomberg BNA - Pharmaceutical Law & Industry Report discussing how the PTAB may be taking a more balanced approach in biotech and pharmaceutical IPRs.
The PTAB May Be Taking a More Balanced Approach in Biotech and Pharmaceutical IPRs from Knobbe Martens Olson & Bear
Reproduced with permission from Pharmaceutical Law & Industry Report, 13 PLIR 378, 03/13/2015. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com